Recruiting studies: Gastric Cancer Adenocarcinoma Of Esophagogastric Junction

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
Phase 2 · 2 location(s) · Mayo Clinic · NCT05969860 Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
Phase 1 · 21 location(s) · I-Mab Biopharma US Limited · NCT04900818 Disitamab Vedotin Plus Trastuzumab in Patients With HER2 Positive GC/GEJ Patiens
Phase 1/Phase 2 · 1 location(s) · Zhejiang Cancer Hospital · NCT06572319 A Study of PD-1 Inhibitors Combined With Fruquintinib and Chemotherapy in First-line Treatment of HER2-negative Advanced
NA · 1 location(s) · Fudan University · NCT06158919 A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
Phase 1 · 10 location(s) · Dren Bio · NCT06999187 SHR-1701 With or Without Apatinib in Combination With Chemotherapy as Neoadjuvant Therapy for Gastric Cancer
Phase 2 · 1 location(s) · The First Affiliated Hospital with Nanjing Medical Universit · NCT07464756 Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma.
Phase 2 · 11 location(s) · RemeGen Co., Ltd. · NCT06155383 A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
Phase 3 · 249 location(s) · Astellas Pharma Global Development, Inc. · NCT06901531 First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2)
Phase 2 · 20 location(s) · Qilu Hospital of Shandong University · NCT06730373 KN026 in Combination With Chemotherapy in HER2 Positive Gastric Cancer Subjects Who Have Failed First-line Therapy
Phase 2/Phase 3 · 1 location(s) · Shanghai JMT-Bio Inc. · NCT05427383 Tislelizumab in Combination With Pre-operative CRT Versus SOC for Locally Advanced G/GEJ Adenocarcinoma
Phase 2 · 3 location(s) · The Affiliated Nanjing Drum Tower Hospital of Nanjing Univer · NCT05687357 A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors
Phase 1 · 10 location(s) · Epkin · NCT06789172 Sintilimab Combined With Chemotherapy as Adjuvant Treatment for Phase III GC and GEJ
Phase 2 · 1 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT06761846 A Study of Fruquintinib Plus Chemotherapy for Postoperative Treatment of HER2-Negative Gastric Cancer With Poor TRG
Phase 2 · 1 location(s) · Henan Cancer Hospital · NCT06774222 QL1706 Combined With SOX Used in Theperioperative Treatment
Phase 1/Phase 2 · 1 location(s) · Xiangdong Cheng · NCT06766305 Study of Suratadenoturev (OBP-301) in Combination With Pembrolizumab in Esophagogastric Adenocarcinoma
Phase 2 · 2 location(s) · Weill Medical College of Cornell University · NCT06340711 Chemoradiotherapy and SHR-1701 in Patients With Unresectable Gastric Cancer
Phase 2 · 3 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT07689851 Dual-target CLDN18.2/HER2 CAR-NK Cells for Advanced Gastric/GEJ Cancer
Phase 1/Phase 2 · 1 location(s) · Beijing Biotech · NCT07551362 Albumin-bound Paclitaxel-based Second-line Treatment Regimens for Locally Advanced or Metastatic G/GEJ Adenocarcinoma
Phase N/A · 1 location(s) · Fudan University · NCT07389876 A Study of KK2269 in Adult Participants With Solid Tumors
Phase 1 · 11 location(s) · Kyowa Kirin Co., Ltd. · NCT06266299 XELOX Combined With Sintilimab and HBO for Advanced or Metastatic GC/GEJC
Phase 1/Phase 2 · 2 location(s) · West China Hospital · NCT06742411 A Study of Trastuzumab DeRuxtecan for Patients With Advanced HER2-pOsitive GaStric or GastroesoPhageal Junction AdEnocar
Phase N/A · 76 location(s) · Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company · NCT05993234 Zimberelimab Anti-PD1 +/- Domvanalimab in Resectable Mmrd Gastric Cancer
Phase 2 · 9 location(s) · Royal Marsden NHS Foundation Trust · NCT06250036 DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinom
Phase 2/Phase 3 · 12 location(s) · RemeGen Co., Ltd. · NCT06221748 XNW27011 Study of Advanced Solid Tumor Subjects Who Failed Standard Therapies.
Phase 1/Phase 2 · 1 location(s) · Evopoint Biosciences Inc. · NCT06792435 Safety Comparison of Total Laparoscopic Proximal Gastrectomy With or Without Preservation of the Celiac Branch of the Va
NA · 1 location(s) · Fujian Cancer Hospital · NCT07142122 Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction
Phase 2 · 44 location(s) · AstraZeneca · NCT05702229 A IIT Study of 177Lu-DOTA-SNA040
EARLY_Phase 1 · 1 location(s) · SmartNuclide Biopharma · NCT07595237 mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Neg
Phase 3 · 794 location(s) · Alliance for Clinical Trials in Oncology · NCT05677490 A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
Phase 1/Phase 2 · 13 location(s) · AstraZeneca · NCT07115043

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →